National Health (Pharmaceutical Benefits) Regulations (Amendment)

1. After item 32 insert the following item:

“ 32a Betamethasone Valerate.....................

— ”.

2. After item 41 insert the following item:

“ 41a Cephalexin.............................

Purified Water, B.P., with Cephalexin ”,

3. Omit item 120.

4. After item 133 insert the following item:

“ 133a Miconazole Nitrate.......................

— ”.

5. Omit item 163.

6. Omit item 187.

7. After item 218 insert the following item:

“ 218a Triglycerides Oil, Medium Chain

— ”.

1. Omit item 4, substitute the following items:

“ 4 Alginic Acid Compound Powder

With the written authority of the Director-General, cardio-oesophageal reflux

“ 4a Alginic Acid Compound Granules

With the written authority of the Director-General, cardio oesophageal reflux not responding to antacid therapy ”.

2. Omit item 19, substitute the following item:

“ 19 (1) Calciferol, B.P.

With the written authority of the Director-General—

(2) Calciferol Tablets, Strong, B.P.

Hypocalcaemia

Hypoparathyroidism

Osteomalacia following gastrectomy, severe steatorrhoea or renal failure

Vitamin D-resistant rickets ”.

3. Omit item 23, substitute the following item:

“ 23 Carbenicillin Sodium

Any disease or condition in a patient receiving treatment in or at an approved hospital

With the written authority of the Director-General—

Infections where positive bacteriological evidence confirms that carbenicillin is the most appropriate therapeutic agent

Septicaemia, suspected or proven ”

4. Omit item 26, substitute the following item:

“ 26 Cephaloridine

Endophthalmitis

Infections where positive bacteriological evidence conforms that cephaloridine is the most appropriate therapeutic agent ”.

5. Omit item 39, substitute the following item:

“ 39 (1) Clindamycin Hydrochloride

Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin ”.

(2) Clindamycin Palmilate Hydrochloride

6. Omit item 47, substitute the following item:

“ 47 (1) Cyclophosphamide, B.P.

Any disease or condition in a patient receiving treatment in or at an approved hospital

(2) Cyclophosphamide Tablets, B.P.

With the written authority of the Director-General—

Anaemia, autoimmune, haemolytic

Arthritis, rheumatoid with vasculitis or visceral complications

Continuing cyclophosphamide therapy after discharge from an approved hospital

Crohn’s disease

Dermatomyositis

Granulomatosis, Wegener’s

Hepatitis, active, chronic

Lupus erythematosus, systemic

Malignant disease, including leukaemia

Nephritis

Nephrotic syndrome

Pemphigus vulgaris

Polyarteritis nodosa

Scleroderma

Thrombocytopenic purpura

Ulcerative colitis ”.

7. Omit item 63, substitute the following item:

“ 63 Fluoxymesterone Tablets, B.P.

With the written authority of the Director-General—

Aplastic anemias, proven

Carcinoma of the beast

Hypogonadism

Osteoporosis ”.

8. Omit item 70, substitute the following item:

“ 70 Gentamicin Injection, B.P.

Any disease or condition in a patient receiving treatment in or at an approved hospital

Endophthalmitis

With the written authority of the Director-General—

Infections where positive bacteriological evidence confirms that gentamicin sulphate is the most appropriate antibiotic

Septicaemia including suspected septicaemia ”.

9. Omit item 76, substitute the following item:

“ 76 (1) Haloperidol

Any disease or condition in a patient receiving treatment in or at an approved hospital

(2) Haloperidol Tablets, B.P., 1.5 mg

Chorea

Hyperactive states of organic or toxic delirium

Malignant neoplasia (late stage)

Radiation sickness

Major psychoses including—

Major organic psychoses including arteriopathic dementia

Manic-depressive psychosis

Paranoid states

Schizophrenia

Senile dementia ”.

10. After item 76 insert the following item:

“ 76a Haloperidol Tablets, B.P., 5 mg

For use in a hospital for acute schizophrenia or mania ”.

11. Omit item 88, substitute the following item:

“ 88 (1) Levodopa, B.P., with Carbidopa

Treatment of Parkinson’s Disease ”.

(2) Levodopa Capsules, B.P.

(3) Levodopa Tablets, B.P.

12. Omit item 89.

13. Omit item 90.

14. Omit item 91.

15. Omit item 104, substitute the following item:

“ 104 Methicillin Sodium, B.P., for injection

Endophthalmitis

Proven or suspected staphylococcal septicaemia ”.

16. Omit item 107, substitute the following item:

“ 107 Methylprednisolone Acetate Injection

For local intra-articular or peri-articular infiltration ”.

17. Omit item 110, substitute the following item:

“ 110 (1) Methylteslosterone, B.P.

Carcinoma of the breast

(2) Methyltestosterone Tablets, B.P., 25 mg or 50 mg

Hypogonadism

Klinefelter’s syndrome (seminiferous tubule dysgenesis) ”.

18. After item 111 insert the following items:

“ 111a Metoprolol Tartrate

With the written authority of the Director-General, frequent disabling angina without evidence of cardiac failure

“ 111b Miconazole Nitrate

Cutaneous candidiasis

Dermatomycosis

Pityriasis versicolor ”.

19. Omit item 115, substitute the following item:

“ 115 Nandrolone Decanoate Injection, B.P.

With the written authority of the Director-General—

Carcinoma of the breast

Osteoporosis

Patients on long-term treatment with corticosteroids ”.

20.

Omit item 116, substitute the following item:

“ 116 Nandrolone Phenylpropionate Injection, B.P.

With the written authority of the Director-General—

Carcinoma of the breast

Osteoporosis

Patients on long-term treatment with corticosteroids ”.

21.

Omit item 129.

22.

Omit item 132, substitute the following item:

“ 132 Phenelzine Tablets, B.P.

Depressive illness resistant to treatment with tricyclic antidepressants or electroconvulsive therapy

Phobic states ”.

23.

Omit item 152.

24.

Omit item 155, substitute the following item:

“ 155 Sodium Nitroprusside

For use in a hospital ”.

25.

Omit item 158, substitute the following item:

“ 158 Stanolone Tablets, B.P.

With the written authority of the Director-General—

Carcinoma of the breast

Osteoporosis

Patients on long-term treatment with corticosteroids ”.

26.

Omit item 167, substitute the following item:

“ 167 Thiamine Hydrochloride Tablets, B.P.

Any disease or condition in a pensioner ”.

27.

Omit item 172, substitute the following item:

“ 172 Tranylcypromine Tablets, B.P.

Depressive illness resistant to treatment with tricyclic anti-depressants or electroconvulsive therapy

Phobic states ”.

28.

After item 174 insert the following item:

“ 174a Triglycerides Oil, Medium Chain

With the written authority of the Director-General, patients requiring a ketogenic diet for intractable childhood epilepsy ”.

29.

Omit item 175, substitute the following item:

“ 175 ‘ TRIGLYDE ’

With the written authority of the Director-General—

Patients requiring a ketogenic diet for intractable childhood epilepsy

Proven malabsorption ”.

30.

Omit item 177, substitute the following item:

“ 177 Vancomycin Hydrochloride

Any disease or condition in a patient receiving treatment in a hospital

Endophthalmitis ”;